Pembrolizumab Plus Placebo News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pembrolizumab plus placebo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pembrolizumab Plus Placebo Today - Breaking & Trending Today

Pembrolizumab/Lenvatinib Regimens Miss Survival End Points in Metastatic NSCLC

The first-line combination of pembrolizumab, lenvatinib, pemetrexed, and platinum-containing chemotherapy did not meet the dual primary end points of overall survival and progression-free survival compared with pembrolizumab plus pemetrexed and platinum-containing chemotherapy in patients with metastatic, nonsquamous non–small cell lung cancer in whom EGFR-, ALK- or ROS1-directed therapies were not indicated. ....

Gregory Lubiniecki , Corina Dutcus , Merck Research Laboratories , Pembrolizumab And Lenvatinib , Pembrolizumab Plus Placebo , Eisai Inc , Metastatic Nsclc , Phase 3 Leap 006 Trial Nct03829319 ,

LEAP-010 Trial Discontinued After OS Projection With Pembrolizumab/Lenvatinib in Metastatic HNSCC

The combination of pembrolizumab and lenvatinib demonstrated a statistically significant improvement in progression-free survival and objective response rate but failed to improve overall survival compared with pembrolizumab plus placebo as frontline therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma. ....

United States , Corina Dutcus , Gregory Lubiniecki , Oncology At Eisai Inc , Global Clinical Development At Merck Research Laboratories , Global Clinical Development , Data Monitoring Committee , European Union , Merck Research Laboratories , Eisai Inc , Pembrolizumab And Lenvatinib , Pembrolizumab Plus Placebo , Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma , Leap 010 Trial , Eisai Inc ,